Wulfmeyer, Vera C. Auber, Bernd Haller, Hermann Schmitt, Roland
Published in
American Journal of Nephrology
Background: Tolvaptan can slow down renal function decline in autosomal dominant polycystic kidney disease (ADPKD). While there is consensus across international recommendations that the drug should only be used in patients with high risk of rapid progression, identification criteria for rapid progression vary. Here, we investigated different asse...
Straube, Christoph Kessel, Kerstin A. Zimmer, Claus Schmidt-Graf, Friederike Schlegel, Jürgen Gempt, Jens Meyer, Bernhard Combs, Stephanie E.
Published in
Current Treatment Options in Oncology
The treatment of malignant gliomas has undergone a significant intensification during the past decade, and the interdisciplinary treatment team has learned that all treatment opportunities, including surgery and radiotherapy (RT), also have a central role in recurrent gliomas. Throughout the decades, re-irradiation (re-RT) has achieved a prominent ...
Cintra, Marco Túlio Gualberto Belém, Dinah Moraes, Edgar Nunes Botoni, Fernando Antônio Bicalho, Maria Aparecida Camargos
SUMMARY OBJECTIVE To review systematically the influence of admission criteria on the mortality of elderly patients under intensive therapy. METHODS We performed a search on the PUBMED and BIREME databases by using the MeSH and DeCS terms “intensive care units”, “patient admission”, and “aged” in Portuguese, English, and Spanish. Only prospective a...
van der Zijden, Thijs Mondelaers, Annelies Yperzeele, Laetitia Voormolen, Maurits Parizel, Paul M.
Published in
Insights into Imaging
During the last decade, the management of acute ischemic stroke has changed dramatically, from an expectant bedside “wait and see” attitude towards active treatment, thanks to the continuous improvement of new therapeutic options. In addition to the use of intravenous (IV) thrombolysis in emergent large vessel occlusion (ELVO), endovascular therapy...
Schütte, Wolfgang Möller, Miriam
Published in
Karger Kompass Onkologie
Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss...
Rose, Olaf Richling, Ina Voigt, Karen Gottschall, Mandy Köberlein-Neu, Juliane
Published in
Research in social & administrative pharmacy : RSAP
Implementation of collaborative Medication Review (MR) into routine care faces several barriers. The study aim was to gain information on patient selection for a MR by general practitioners (GPs). GP selection was compared to objective selection criteria on identifying patients, who would benefit from a MR the most. A secondary objective of this st...
Niesen, Willem Primavesi, Florian Gasteiger, Silvia Neoptolemos, John Hackert, Thilo Stättner, Stefan
Published in
European Surgery
BackgroundPancreatic cancer (PC) remains a disease characterized by an extremely poor prognosis, which is often limited by advanced tumor stage at diagnosis. As surgery remains the only option for long-term survival, indications for resection to achieve a complete tumor removal have been extended in recent years, including locally advanced as well ...
Sukul, Nidhi Zhao, Junhui Fuller, Douglas S. Karaboyas, Angelo Bieber, Brian Sloand, James A. Subramanian, Lalita Johnson, David W. Oliver, Matthew J. Tungsanga, Kriang
...
Published in
BMC Nephrology
BackgroundPatient-reported measures are increasingly recognized as important predictors of clinical outcomes in peritoneal dialysis (PD). We sought to understand associations between patient-reported perceptions of the advantages and disadvantages of PD and clinical outcomes.MethodsIn this cohort study, 2760 PD patients in the Peritoneal Dialysis O...
Bekaii-Saab, Tanios Kim, Richard Kim, Tae Won O'Connor, Juan Manuel Strickler, John H Malka, David Sartore-Bianchi, Andrea Bi, Feng Yamaguchi, Kensei Yoshino, Takayuki
...
Published in
Clinical colorectal cancer
An increasing number of patients with metastatic colorectal cancer (mCRC) are able to receive 3 or more lines of therapy. Treatments in this setting can include regorafenib (an oral multikinase inhibitor), trifluridine/tipiracil hydrochloride (TAS-102), antibodies that target epidermal growth factor receptor for patients with RAS wild-type tumors (...
Schütte, Wolfgang Möller, Miriam
Published in
Karger Kompass Pneumologie
Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss...
